ResMed opens the week with clear technical signals, shares trade in a defined range
24.06.2026 - 10:52:45 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-24, 10:43.
ResMed Inc. (US7611521078) opened the new week on NASDAQ with a clearly defined technical setup around its recent close near 191.30 US dollars per share. According to TradingKey data for the session ending June 23, the shares gained 1.51 percent and sit within a medium-term trading range between support at 177.16 dollars and resistance at 208.46 dollars TradingKey technical overview.
What the technicals show
TradingKey currently assigns ResMed a price momentum score of 7.06, placing the stock 80th out of 204 names in the Healthcare Equipment & Supplies industry by that metric, which underlines a mid-field momentum position among sector peers such as Medtronic and Philips TradingKey technical overview. The same source highlights that the shares are trading between clearly identified support at 177.16 dollars and resistance at 208.46 dollars, which characterizes the current pattern as suitable for range-bound swing trading strategies.
Across moving averages from 5 to 200 days, TradingKey counts one short-term buy signal versus five sell signals, resulting in an overall daily trading signal classified as "Sell" in the technical toolbox for June 23 TradingKey moving-average signals. This configuration reflects a price that has recovered from earlier lows but still faces resistance clusters above the current level.
Analyst views and recent news
On the fundamental side, KeyBanc Capital Markets recently adjusted its view on ResMed, trimming the price target to 266 dollars from 290 dollars while reiterating an Overweight rating on the shares, signaling that the broker still sees upside potential despite a more cautious target level KeyBanc update cited in Intellectia.ai. The revised target implies a material premium to the current trading zone around 191 dollars, illustrating the spread between near-term technical signals and the longer-horizon analyst model.
In late April, ResMed also communicated changes in its governance structure, announcing the planned departure of certain directors and officers, which was noted in the same Intellectia.ai summary and referenced to moomoo as the originating platform Governance changes summary. Such board and executive-level adjustments typically feed into institutional assessments of corporate oversight but have not altered the Overweight stance at KeyBanc.
All news and key data on the ResMed shares
Further price data, company announcements and background on ResMed can be found in the dedicated topic overview and on the company’s investor relations pages.
How ResMed makes its money
ResMed generates the bulk of its revenue from equipment and software for the diagnosis, treatment and long-term management of sleep-disordered breathing and other chronic respiratory conditions, with continuous positive airway pressure devices and associated masks forming a central hardware line alongside cloud-connected patient monitoring platforms detailed on the company’s website ResMed corporate overview.
Where the shares trade now
The ResMed shares (US7611521078) last closed on NASDAQ on 2026-06-23 at 191.30 US dollars, according to TradingKey, with a reported market capitalization of approximately 27.74 billion dollars for the company at that time TradingKey price snapshot.
Key data on the ResMed shares
- Company: ResMed Inc.
- ISIN: US7611521078
- WKN: 895601
- Ticker: RMD
- Trading venue: NASDAQ
- Price (as of 2026-06-23, 16:00): 191.30 USD
- Market cap: 27.74 billion USD (as of 2026-06-23)
- Sector / industry: Health Care Equipment & Supplies
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.
